medwireNews: Osimertinib significantly improves outcomes relative to gefitinib or erlotinib in treatment-naïve patients with advanced epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC), the phase III FLAURA trial shows.
Lead author Suresh Ramalingam (Winship Cancer Institute of Emory University, Atlanta, Georgia, USA) told the press at the ESMO 2017 Congress in Madrid, Spain, that the third-generation EGFR tyrosine kinase inhibitor (TKI) is “a new standard of care” for the first-line treatment of this patient population.
We see the next step forward as osimertinib, and we are already beginning to think about what's beyond osimertinib.
Progression-free survival was significantly longer for the 279 patients randomly assigned to receive osimertinib 80 mg/day than for the 277 given the current standard of care (gefitinib 250 mg/day or erlotinib 150 mg/day), at a median of 18.9 versus 10.2 months and a hazard ratio (HR) of 0.46.
And although the overall survival data are “relatively immature” at present, said Ramalingam, the HR of 0.63 at this interim analysis suggests “a strong and promising survival trend.”
medwireNews is an independent medical news service provided by Springer Healthcare. © 2017 Springer Healthcare part of the Springer Nature group